1. Among patients with high-risk, early-stage triple-negative breast cancer, the addition of carboplatin to a standard anthracycline/taxane adjuvant chemotherapy regimen ...
1. Progression-free survival was significantly greater in retifanlimab compared to placebo. 2. Serious and grade 3 or more adverse events ...
1. Adjuvant carboplatin intensified chemotherapy was superior to standard chemotherapy in improving survival outcomes in patients with high-risk, early-stage, triple-negative ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There were fewer treatment-related and serious adverse ...
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
Click to read this study in JAMA Otolaryngology - Head & Neck Surgery.
Click to read this study in Clinical Cancer Research.
Click to read this study in The Lancet Oncology.
Click to read this study in JAMA Network Open.
